BindingDB logo
myBDB logout

Patent code US8507533

Compile Data Set for Download or QSAR
Found 84 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)		LigandTarget/Host
Links		Ligand
Links		Trg + Lig
Links		Ki
nM		ΔG°
kJ/mole		IC50
nM		Kd
nM		EC50/IC50
nM		koff
s-1		kon
M-1s-1		pHTemp
°C
Pro-glucagon


(Homo sapiens (Human))		BDBM2437
PNG
(US8507533, 157)
Show SMILES CC1(C)CC(C1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H27F3N6O3/c1-24(2)9-17(10-24)21(15-3-5-16(6-4-15)22(37)29-8-7-20(35)36)33-19-12-30-23(31-13-19)34-14-18(11-32-34)25(26,27)28/h3-6,11-14,17,21,33H,7-10H2,1-2H3,(H,29,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 5.55n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 5.75n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 7.60n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2390
PNG
(US8507533, 146)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 |r|
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 9.05n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 15.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100796
PNG
(US8507533, 101)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 17n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 20.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2376
PNG
(US8507533, 137)
Show SMILES CCC[C@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 20.2n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 25.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2391
PNG
(US8507533, 147)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 |r|
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 26.7n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100850
PNG
(US8507533, 168)
Show SMILES CC(C)C[C@@H](Nc1ccc(cn1)C(=O)NCCC(O)=O)c1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F |r|
Show InChI InChI=1S/C26H30F3N5O3/c1-15(2)9-21(33-22-6-5-18(12-31-22)25(37)30-8-7-23(35)36)19-10-16(3)24(17(4)11-19)34-14-20(13-32-34)26(27,28)29/h5-6,10-15,21H,7-9H2,1-4H3,(H,30,37)(H,31,33)(H,35,36)/t21-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 27.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100852
PNG
(US8507533, 170 | US8507533, 419)
Show SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1
Show InChI InChI=1S/C27H30F3N5O3/c1-16-11-20(12-17(2)25(16)35-15-21(14-33-35)27(28,29)30)24(18-5-3-4-6-18)34-22-8-7-19(13-32-22)26(38)31-10-9-23(36)37/h7-8,11-15,18,24H,3-6,9-10H2,1-2H3,(H,31,38)(H,32,34)(H,36,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 28n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 29n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 29.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2241
PNG
(US8507533, 136)
Show SMILES CCC[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 30.2n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100838
PNG
(US8507533, 153)
Show SMILES CCCC(Oc1cc(C)c(c(OC)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O5/c1-4-5-21(17-6-8-18(9-7-17)25(35)30-11-10-23(33)34)37-20-12-16(2)24(22(13-20)36-3)32-15-19(14-31-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 32.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2240
PNG
(US8507533, 135)
Show SMILES CC1(C)CC(C1)[C@H](Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)/t23-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 35n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100837
PNG
(US8507533, 152)
Show SMILES Cc1cc(OC(C2CC(C)(C)C2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C29H32F3N3O4/c1-17-11-23(12-18(2)25(17)35-16-22(15-34-35)29(30,31)32)39-26(21-13-28(3,4)14-21)19-5-7-20(8-6-19)27(38)33-10-9-24(36)37/h5-8,11-12,15-16,21,26H,9-10,13-14H2,1-4H3,(H,33,38)(H,36,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 35.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100805
PNG
(US8507533, 113)
Show SMILES CCCC(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C22H23F3N6O3/c1-2-3-18(14-4-6-15(7-5-14)20(34)26-9-8-19(32)33)30-17-11-27-21(28-12-17)31-13-16(10-29-31)22(23,24)25/h4-7,10-13,18,30H,2-3,8-9H2,1H3,(H,26,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 38.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2438
PNG
(US8507533, 158)
Show SMILES CCOC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)C1CC(C)(C)C1
Show InChI InChI=1S/C27H31F3N6O3/c1-4-39-22(37)9-10-31-24(38)18-7-5-17(6-8-18)23(19-11-26(2,3)12-19)35-21-14-32-25(33-15-21)36-16-20(13-34-36)27(28,29)30/h5-8,13-16,19,23,35H,4,9-12H2,1-3H3,(H,31,38)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 41n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100861
PNG
(US8507533, 188)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
Purchase

PC cid
PC sid
PDB
UniChem

Similars
US Patent
 42.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100864
PNG
(US8507533, 193)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 44.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100815
PNG
(US8507533, 122)
Show SMILES CC(C)(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C28H35N5O3/c1-28(2,3)23-17-33(18-31-23)24-13-12-22(16-30-24)32-26(19-6-4-5-7-19)20-8-10-21(11-9-20)27(36)29-15-14-25(34)35/h8-13,16-19,26,32H,4-7,14-15H2,1-3H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 45.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 47.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2229
PNG
(US8507533, 187 | US8507533, 448)
Show SMILES CCC[C@H](Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)/t26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 47.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100824
PNG
(US8507533, 131)
Show SMILES Cc1cc(OC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cnc(c1)C(F)(F)F
Show InChI InChI=1S/C28H30F3N3O4/c1-17-13-22(14-18(2)25(17)34-15-23(33-16-34)28(29,30)31)38-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(37)32-12-11-24(35)36/h7-10,13-16,19,26H,3-6,11-12H2,1-2H3,(H,32,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 51n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100801
PNG
(US8507533, 109 | US8507533, 322)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1F)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H23F4N5O3/c1-2-3-19(17-6-4-14(10-18(17)24)22(35)28-9-8-21(33)34)31-16-5-7-20(29-12-16)32-13-15(11-30-32)23(25,26)27/h4-7,10-13,19,31H,2-3,8-9H2,1H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 57.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2387
PNG
(US8507533, 143)
Show SMILES CC(C)C[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cn1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C23H25F3N6O3/c1-14(2)9-19(18-5-3-15(10-28-18)22(35)27-8-7-21(33)34)31-17-4-6-20(29-12-17)32-13-16(11-30-32)23(24,25)26/h3-6,10-14,19,31H,7-9H2,1-2H3,(H,27,35)(H,33,34)/t19-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 57.4n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100826
PNG
(US8507533, 133)
Show SMILES CCCC(Oc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H28N4O4/c1-2-6-25(21-9-11-22(12-10-21)28(35)29-16-15-27(33)34)36-24-13-14-26(30-18-24)32-19-23(17-31-32)20-7-4-3-5-8-20/h3-5,7-14,17-19,25H,2,6,15-16H2,1H3,(H,29,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 58n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100831
PNG
(US8507533, 144)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H33N3O4/c1-4-5-25(21-8-10-22(11-9-21)28(34)29-13-12-26(32)33)35-24-14-18(2)27(19(3)15-24)31-17-23(16-30-31)20-6-7-20/h8-11,14-17,20,25H,4-7,12-13H2,1-3H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 62.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100829
PNG
(US8507533, 140)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(Cl)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26ClN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-11-9-22(10-12-23)31-17-20-16-21(28)8-13-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 62.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100847
PNG
(US8507533, 163)
Show SMILES Cc1nn(cc1Cl)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C25H28ClN5O3/c1-16-21(26)15-31(30-16)22-11-10-20(14-28-22)29-24(17-4-2-3-5-17)18-6-8-19(9-7-18)25(34)27-13-12-23(32)33/h6-11,14-15,17,24,29H,2-5,12-13H2,1H3,(H,27,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 65.9n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100797
PNG
(US8507533, 105)
Show SMILES CC(C)CC(Nc1cnc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28F3N5O3/c1-15(2)10-21(17-4-6-18(7-5-17)24(36)29-9-8-22(34)35)32-20-11-16(3)23(30-13-20)33-14-19(12-31-33)25(26,27)28/h4-7,11-15,21,32H,8-10H2,1-3H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 69.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100799
PNG
(US8507533, 107)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CC1CC1)Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)21-8-7-19(13-29-21)31-20(11-15-1-2-15)16-3-5-17(6-4-16)23(35)28-10-9-22(33)34/h3-8,12-15,20,31H,1-2,9-11H2,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 71.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100856
PNG
(US8507533, 181)
Show SMILES CC(C)(C)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26F3N5O3/c1-23(2,3)21(15-4-6-16(7-5-15)22(35)28-11-10-20(33)34)31-17-8-9-19(29-12-17)32-13-18(30-14-32)24(25,26)27/h4-9,12-14,21,31H,10-11H2,1-3H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 87.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100816
PNG
(US8507533, 123)
Show SMILES CC(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C27H33N5O3/c1-18(2)23-16-32(17-30-23)24-12-11-22(15-29-24)31-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(35)28-14-13-25(33)34/h7-12,15-19,26,31H,3-6,13-14H2,1-2H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 88.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100830
PNG
(US8507533, 141)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-21(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-20-12-16(2)24(17(3)13-20)32-14-22(31-15-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 89.5n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100798
PNG
(US8507533, 106)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCC1
Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)20-9-8-19(13-29-20)31-22(15-2-1-3-15)16-4-6-17(7-5-16)23(35)28-11-10-21(33)34/h4-9,12-15,22,31H,1-3,10-11H2,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 91.9n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100794
PNG
(US8507533, 300 | US8507533, 97 | US8507533, 98)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C25H26F3N5O3/c26-25(27,28)20-14-33(15-31-20)21-10-9-19(13-30-21)32-23(16-3-1-2-4-16)17-5-7-18(8-6-17)24(36)29-12-11-22(34)35/h5-10,13-16,23,32H,1-4,11-12H2,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 93n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100823
PNG
(US8507533, 130 | US8507533, 369)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(Cl)cn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28ClN3O4/c1-4-5-22(18-6-8-19(9-7-18)25(32)27-11-10-23(30)31)33-21-12-16(2)24(17(3)13-21)29-15-20(26)14-28-29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,27,32)(H,30,31)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 93.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2408
PNG
(US8507533, 155)
Show SMILES CC1(C)CC(C1)C(Oc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H26F3N5O4/c1-24(2)9-17(10-24)21(15-3-5-16(6-4-15)22(36)29-8-7-20(34)35)37-19-12-30-23(31-13-19)33-14-18(11-32-33)25(26,27)28/h3-6,11-14,17,21H,7-10H2,1-2H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 94.9n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100818
PNG
(US8507533, 125)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cccc(C)c2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-5-25(20-8-10-21(11-9-20)28(34)29-17-16-26(32)33)35-24-14-12-23(13-15-24)31-18-22-7-4-6-19(2)27(22)30-31/h4,6-15,18,25H,3,5,16-17H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 98.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100854
PNG
(US8507533, 176)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H29N5O3/c1-2-3-22(18-6-8-19(9-7-18)25(33)26-13-12-24(31)32)29-21-10-11-23(27-15-21)30-16-20(14-28-30)17-4-5-17/h6-11,14-17,22,29H,2-5,12-13H2,1H3,(H,26,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 101n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100812
PNG
(US8507533, 119)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Oc1ccc(cc1)-n1cc2ccccc2n1)C1CCCC1
Show InChI InChI=1S/C29H29N3O4/c33-27(34)17-18-30-29(35)22-11-9-21(10-12-22)28(20-5-1-2-6-20)36-25-15-13-24(14-16-25)32-19-23-7-3-4-8-26(23)31-32/h3-4,7-16,19-20,28H,1-2,5-6,17-18H2,(H,30,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 103n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100860
PNG
(US8507533, 187 | US8507533, 189 | US8507533, 450)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 109n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100817
PNG
(US8507533, 124)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H27N3O4/c1-2-5-25(19-8-10-20(11-9-19)27(33)28-17-16-26(31)32)34-23-14-12-22(13-15-23)30-18-21-6-3-4-7-24(21)29-30/h3-4,6-15,18,25H,2,5,16-17H2,1H3,(H,28,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 109n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2232
PNG
(US8507533, 134)
Show SMILES CC1(C)CC(C1)[C@@H](Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)/t23-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
Purchase

MCE
PC cid
PC sid
PDB
UniChem

Similars
US Patent
 110n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100823
PNG
(US8507533, 130 | US8507533, 369)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(Cl)cn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28ClN3O4/c1-4-5-22(18-6-8-19(9-7-18)25(32)27-11-10-23(30)31)33-21-12-16(2)24(17(3)13-21)29-15-20(26)14-28-29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,27,32)(H,30,31)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 116n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100833
PNG
(US8507533, 148)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(nn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H27F3N4O4/c1-4-5-20(17-6-8-18(9-7-17)24(35)29-11-10-22(33)34)36-19-12-15(2)23(16(3)13-19)32-14-21(30-31-32)25(26,27)28/h6-9,12-14,20H,4-5,10-11H2,1-3H3,(H,29,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 125n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100825
PNG
(US8507533, 132)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cn1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H28N6O3/c1-2-6-24(23-11-9-20(15-29-23)27(36)28-14-13-26(34)35)32-22-10-12-25(30-17-22)33-18-21(16-31-33)19-7-4-3-5-8-19/h3-5,7-12,15-18,24,32H,2,6,13-14H2,1H3,(H,28,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 132n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100858
PNG
(US8507533, 185)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(F)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26FN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-11-9-22(10-12-23)31-17-20-16-21(28)8-13-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 137n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100849
PNG
(US8507533, 165)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)N(C)CCC(O)=O
Show InChI InChI=1S/C29H31N5O3/c1-3-7-26(22-10-12-23(13-11-22)29(37)33(2)17-16-28(35)36)32-25-14-15-27(30-19-25)34-20-24(18-31-34)21-8-5-4-6-9-21/h4-6,8-15,18-20,26,32H,3,7,16-17H2,1-2H3,(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 142n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100803
PNG
(US8507533, 111 | US8507533, 325)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1C)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26F3N5O3/c1-3-4-20(19-7-5-16(11-15(19)2)23(35)28-10-9-22(33)34)31-18-6-8-21(29-13-18)32-14-17(12-30-32)24(25,26)27/h5-8,11-14,20,31H,3-4,9-10H2,1-2H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 143n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100801
PNG
(US8507533, 109 | US8507533, 322)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1F)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H23F4N5O3/c1-2-3-19(17-6-4-14(10-18(17)24)22(35)28-9-8-21(33)34)31-16-5-7-20(29-12-16)32-13-15(11-30-32)23(25,26)27/h4-7,10-13,19,31H,2-3,8-9H2,1H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 153n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100819
PNG
(US8507533, 126)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2ccc(C)cc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-4-26(20-7-9-21(10-8-20)28(34)29-16-15-27(32)33)35-24-13-11-23(12-14-24)31-18-22-6-5-19(2)17-25(22)30-31/h5-14,17-18,26H,3-4,15-16H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 161n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100859
PNG
(US8507533, 186)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2ccc(F)cc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26FN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-12-10-22(11-13-23)31-17-20-8-9-21(28)16-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 175n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100810
PNG
(US8507533, 117 | US8507533, 118 | US8507533, 337)
Show SMILES Cc1cc(ccc1C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCCC1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H30F3N5O3/c1-17-13-21(35-16-20(15-33-35)27(28,29)30)8-9-22(17)25(18-5-3-2-4-6-18)34-23-10-7-19(14-32-23)26(38)31-12-11-24(36)37/h7-10,13-16,18,25H,2-6,11-12H2,1H3,(H,31,38)(H,32,34)(H,36,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 183n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100848
PNG
(US8507533, 164)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H28N6O3/c1-2-5-24(19-7-9-20(10-8-19)27(36)29-15-13-26(34)35)32-22-11-12-25(30-17-22)33-18-21(16-31-33)23-6-3-4-14-28-23/h3-4,6-12,14,16-18,24,32H,2,5,13,15H2,1H3,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 192n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100851
PNG
(US8507533, 169)
Show SMILES CC(C)C[C@H](Nc1ccc(cn1)C(=O)NCCC(O)=O)c1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F |r|
Show InChI InChI=1S/C26H30F3N5O3/c1-15(2)9-21(33-22-6-5-18(12-31-22)25(37)30-8-7-23(35)36)19-10-16(3)24(17(4)11-19)34-14-20(13-32-34)26(27,28)29/h5-6,10-15,21H,7-9H2,1-4H3,(H,30,37)(H,31,33)(H,35,36)/t21-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 193n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100803
PNG
(US8507533, 111 | US8507533, 325)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1C)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26F3N5O3/c1-3-4-20(19-7-5-16(11-15(19)2)23(35)28-10-9-22(33)34)31-18-6-8-21(29-13-18)32-14-17(12-30-32)24(25,26)27/h5-8,11-14,20,31H,3-4,9-10H2,1-2H3,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 202n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100800
PNG
(US8507533, 108)
Show SMILES CCCC(Oc1ccc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H26F3N3O4/c1-3-4-22(17-5-7-18(8-6-17)24(34)29-12-11-23(32)33)35-20-9-10-21(16(2)13-20)31-15-19(14-30-31)25(26,27)28/h5-10,13-15,22H,3-4,11-12H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 203n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100821
PNG
(US8507533, 128)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(C)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-4-26(20-6-8-21(9-7-20)28(34)29-16-15-27(32)33)35-24-12-10-23(11-13-24)31-18-22-17-19(2)5-14-25(22)30-31/h5-14,17-18,26H,3-4,15-16H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 208n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100852
PNG
(US8507533, 170 | US8507533, 419)
Show SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1
Show InChI InChI=1S/C27H30F3N5O3/c1-16-11-20(12-17(2)25(16)35-15-21(14-33-35)27(28,29)30)24(18-5-3-4-6-18)34-22-8-7-19(13-32-22)26(38)31-10-9-23(36)37/h7-8,11-15,18,24H,3-6,9-10H2,1-2H3,(H,31,38)(H,32,34)(H,36,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 224n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100813
PNG
(US8507533, 120)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(Cl)c1)C1CCCC1
Show InChI InChI=1S/C24H26ClN5O3/c25-20-14-30(15-28-20)21-10-9-19(13-27-21)29-23(16-3-1-2-4-16)17-5-7-18(8-6-17)24(33)26-12-11-22(31)32/h5-10,13-16,23,29H,1-4,11-12H2,(H,26,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 225n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100793
PNG
(US8507533, 86)
Show SMILES CCCC(Oc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H23F3N4O4/c1-2-3-19(15-4-6-16(7-5-15)22(33)27-11-10-21(31)32)34-18-8-9-20(28-13-18)30-14-17(12-29-30)23(24,25)26/h4-9,12-14,19H,2-3,10-11H2,1H3,(H,27,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 233n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100839
PNG
(US8507533, 154)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)C1CC(F)(F)C1
Show InChI InChI=1S/C24H22F5N5O3/c25-23(26)9-16(10-23)21(14-1-3-15(4-2-14)22(37)30-8-7-20(35)36)33-17-5-6-19(31-11-17)34-12-18(32-13-34)24(27,28)29/h1-6,11-13,16,21,33H,7-10H2,(H,30,37)(H,35,36)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 235n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100857
PNG
(US8507533, 184)
Show SMILES CCCC(Oc1cc(F)c(c(F)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H22F5N3O4/c1-2-3-20(14-4-6-15(7-5-14)23(35)30-9-8-21(33)34)36-17-10-18(25)22(19(26)11-17)32-13-16(12-31-32)24(27,28)29/h4-7,10-13,20H,2-3,8-9H2,1H3,(H,30,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 240n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2417
PNG
(US8507533, 156)
Show SMILES CCOC(=O)CCNC(=O)c1ccc(cc1)C(Oc1cnc(nc1)-n1cc(cn1)C(F)(F)F)C1CC(C)(C)C1
Show InChI InChI=1S/C27H30F3N5O4/c1-4-38-22(36)9-10-31-24(37)18-7-5-17(6-8-18)23(19-11-26(2,3)12-19)39-21-14-32-25(33-15-21)35-16-20(13-34-35)27(28,29)30/h5-8,13-16,19,23H,4,9-12H2,1-3H3,(H,31,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 251n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100810
PNG
(US8507533, 117 | US8507533, 118 | US8507533, 337)
Show SMILES Cc1cc(ccc1C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCCC1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H30F3N5O3/c1-17-13-21(35-16-20(15-33-35)27(28,29)30)8-9-22(17)25(18-5-3-2-4-6-18)34-23-10-7-19(14-32-23)26(38)31-12-11-24(36)37/h7-10,13-16,18,25H,2-6,11-12H2,1H3,(H,31,38)(H,32,34)(H,36,37)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 297n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100814
PNG
(US8507533, 121)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)C(F)(F)F
Show InChI InChI=1S/C21H17F6N5O3/c22-20(23,24)15-10-32(11-30-15)16-6-5-14(9-29-16)31-18(21(25,26)27)12-1-3-13(4-2-12)19(35)28-8-7-17(33)34/h1-6,9-11,18,31H,7-8H2,(H,28,35)(H,33,34)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 298n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100843
PNG
(US8507533, 159)
Show SMILES CCCC(Oc1ccc(cc1C)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H26F3N3O4/c1-3-4-22(17-5-7-18(8-6-17)24(34)29-12-11-23(32)33)35-21-10-9-20(13-16(21)2)31-15-19(14-30-31)25(26,27)28/h5-10,13-15,22H,3-4,11-12H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 315n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100820
PNG
(US8507533, 127)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2c(C)cccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-5-26(20-8-10-21(11-9-20)28(34)29-17-16-27(32)33)35-23-14-12-22(13-15-23)31-18-24-19(2)6-4-7-25(24)30-31/h4,6-15,18,26H,3,5,16-17H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 316n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100828
PNG
(US8507533, 139)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cccc(Cl)c2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26ClN3O4/c1-2-4-24(18-7-9-19(10-8-18)27(34)29-16-15-25(32)33)35-22-13-11-21(12-14-22)31-17-20-5-3-6-23(28)26(20)30-31/h3,5-14,17,24H,2,4,15-16H2,1H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 354n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100863
PNG
(US8507533, 190)
Show SMILES CCCC(Nc1ccc(cn1)C(=O)NCCC(O)=O)c1ccc(nc1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C22H23F3N6O3/c1-2-3-17(30-18-6-4-15(11-27-18)21(34)26-9-8-20(32)33)14-5-7-19(28-10-14)31-13-16(12-29-31)22(23,24)25/h4-7,10-13,17H,2-3,8-9H2,1H3,(H,26,34)(H,27,30)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 399n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100855
PNG
(US8507533, 177)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCOCC1
Show InChI InChI=1S/C25H26F3N5O4/c26-25(27,28)19-13-31-33(15-19)21-6-5-20(14-30-21)32-23(17-8-11-37-12-9-17)16-1-3-18(4-2-16)24(36)29-10-7-22(34)35/h1-6,13-15,17,23,32H,7-12H2,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 432n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100835
PNG
(US8507533, 150)
Show SMILES CCCC(Oc1cnc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H25F3N4O4/c1-3-4-20(16-5-7-17(8-6-16)23(34)28-10-9-21(32)33)35-19-11-15(2)22(29-13-19)31-14-18(12-30-31)24(25,26)27/h5-8,11-14,20H,3-4,9-10H2,1-2H3,(H,28,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 446n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100808
PNG
(US8507533, 116)
Show SMILES CCCC(Oc1ccc(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N3O4/c1-3-6-26(20-9-11-21(12-10-20)28(34)29-16-15-27(32)33)35-23-13-14-25(19(2)17-23)31-18-22-7-4-5-8-24(22)30-31/h4-5,7-14,17-18,26H,3,6,15-16H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 464n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100792
PNG
(US8507533, 53)
Show SMILES CCCC(Oc1ccc(cc1)-c1cc(nn1C)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H26F3N3O4/c1-3-4-21(17-5-7-18(8-6-17)24(34)29-14-13-23(32)33)35-19-11-9-16(10-12-19)20-15-22(25(26,27)28)30-31(20)2/h5-12,15,21H,3-4,13-14H2,1-2H3,(H,29,34)(H,32,33)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 556n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM2377
PNG
(US8507533, 142)
Show SMILES CC(C)C[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cn1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C23H25F3N6O3/c1-14(2)9-19(18-5-3-15(10-28-18)22(35)27-8-7-21(33)34)31-17-4-6-20(29-12-17)32-13-16(11-30-32)23(24,25)26/h3-6,10-14,19,31H,7-9H2,1-2H3,(H,27,35)(H,33,34)/t19-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 636n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100789
PNG
(US8507533, 22)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc(Cl)c(C)n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26ClN3O4/c1-3-4-22(17-5-7-18(8-6-17)24(31)26-14-13-23(29)30)32-20-11-9-19(10-12-20)28-15-21(25)16(2)27-28/h5-12,15,22H,3-4,13-14H2,1-2H3,(H,26,31)(H,29,30)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 665n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100834
PNG
(CHEMBL2381830 | US8507533, 149)
Show SMILES CCCC(Oc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C22H22F3N5O4/c1-2-3-18(14-4-6-15(7-5-14)20(33)26-9-8-19(31)32)34-17-11-27-21(28-12-17)30-13-16(10-29-30)22(23,24)25/h4-7,10-13,18H,2-3,8-9H2,1H3,(H,26,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars
US Patent
 1.05E+3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100794
PNG
(US8507533, 300 | US8507533, 97 | US8507533, 98)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C25H26F3N5O3/c26-25(27,28)20-14-33(15-31-20)21-10-9-19(13-30-21)32-23(16-3-1-2-4-16)17-5-7-18(8-6-17)24(36)29-12-11-22(34)35/h5-10,13-16,23,32H,1-4,11-12H2,(H,29,36)(H,34,35)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 1.10E+3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100791
PNG
(US8507533, 31)
Show SMILES CCCCc1ccn(n1)-c1ccc(OC(CCC)c2ccc(cc2)C(=O)NCCC(O)=O)cc1
Show InChI InChI=1S/C27H33N3O4/c1-3-5-7-22-17-19-30(29-22)23-12-14-24(15-13-23)34-25(6-4-2)20-8-10-21(11-9-20)27(33)28-18-16-26(31)32/h8-15,17,19,25H,3-7,16,18H2,1-2H3,(H,28,33)(H,31,32)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 1.33E+3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Pro-glucagon


(Homo sapiens (Human))		BDBM100790
PNG
(US8507533, 28)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc(F)cn1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H24FN3O4/c1-2-3-21(16-4-6-17(7-5-16)23(30)25-13-12-22(28)29)31-20-10-8-19(9-11-20)27-15-18(24)14-26-27/h4-11,14-15,21H,2-3,12-13H2,1H3,(H,25,30)(H,28,29)
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars
US Patent
 1.66E+3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.

US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
* indicates data uncertainty>20%